Anti-PD-1 antibody therapy for epithelial skin malignancies: an investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)
Latest Information Update: 16 Oct 2024
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Carcinoma; Skin cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- 15 Jun 2023 According to an Ono Pharmaceutical media release, this study was conducted at a Keio University Hospital, Japan.
- 15 Jun 2023 According to an Ono Pharmaceutical media release, the comapny has submitted a supplemental application of Opdivo (generic name: nivolumab) Intravenous Infusion (Opdivo) in Japan, to expand its use for the treatment of unresectable advanced or recurrent malignant epithelial tumors, for a partial change in approved items of the manufacturing and marketing approval.
- 27 Nov 2020 New trial record